Element Biosciences vs Illumina
Side-by-side comparison of AI visibility scores, market position, and capabilities
Element Biosciences makes the AVITI benchtop DNA sequencer; raised $277M Series D in 2024 (led by Wellington Management, Samsung) for $680M+ cumulative; install base grew from ~40 to 190+ units in 12 months.
About
Element Biosciences is a genomics company developing next-generation DNA sequencing instruments and reagents designed to democratize access to high-quality, cost-effective sequencing. Founded in 2017 by veterans from Illumina, Life Technologies, and other genomics leaders, the company is headquartered in San Diego, California. Its flagship product, the AVITI System, is a benchtop sequencer that combines high accuracy, flexible throughput, and competitive per-sample costs — making research-grade sequencing accessible to academic labs, biotech companies, agricultural research programs, and clinical settings that previously could not justify large capital outlays for sequencing infrastructure.
World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clinical genomics, oncology diagnostics, and population-scale sequencing.
About
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applications. The company's sequencing-by-synthesis (SBS) chemistry and NovaSeq, NextSeq, and MiSeq instrument platforms have become the standard infrastructure for genomic research, clinical oncology, reproductive health, and infectious disease diagnostics worldwide.\n\nIllumina's business model combines high-margin consumable sales (flow cells, reagent kits) with instrument placements, creating a razor-and-blades recurring revenue structure. Its clinical sequencing segment showed accelerating growth in 2025, with clinical consumables revenue up 20% year-over-year in Q4. The company is expanding into spatial transcriptomics and multi-omics with new instruments unveiled at AGBT 2025, broadening its addressable market.\n\nIllumina reported $4.34 billion in FY2025 revenue and guides to $4.5–$4.6 billion for FY2026, with non-GAAP operating margins of ~23%. Having divested Grail (its liquid biopsy subsidiary) following regulatory pressure, Illumina is refocused on its core sequencing franchise and positioned to benefit from continued clinical adoption of genomic medicine.
Key Details
Capabilities & Ecosystem
Also Compare
Element Biosciences vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.